Literature DB >> 24924355

Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer.

Yasunori Matsumoto1, Shinji Miwa, Yong Zhang, Yukihiko Hiroshima, Shuya Yano, Fuminari Uehara, Mako Yamamoto, Makoto Toneri, Michael Bouvet, Hisahiro Matsubara, Robert M Hoffman, Ming Zhao.   

Abstract

We report here the efficacy of tumor-targeting Salmonella typhimurium A1-R (A1-R) on mouse models of disseminated and metastatic ovarian cancer. The proliferation-inhibitory efficacy of A1-R on human ovarian cancer cell lines (SKOV-3-GFP, OVCAR-3-RFP) was initially demonstrated in vitro. Orthotopic and dissemination mouse models of ovarian cancer were made with the human ovarian cancer cell line SKOV-3-GFP. After tumor implantation, the mice were treated with A1-R (5 × 10(7)  colony-forming units [CFU], i.v.), and there were no severe adverse events observed. In the orthotopic model, tumor volume after treatment was 276 ± 60.8 mm(3), compared to 930 ± 342 mm(3) in the untreated control group (P = 0.022). There was also a significant difference in survival between treated mice and untreated mice in a peritoneal dissemination model (P = 0.005). The results of this report demonstrate that A1-R is effective for highly aggressive human ovarian cancer in metastatic and dissemination mouse models and suggest its clinical potential for this highly treatment-resistant disease.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  BACTERIA; GFP; IMAGING; NUDE MICE; OVARIAN CANCER; Salmonella typhimurium; TUMOR-TARGETING

Mesh:

Year:  2014        PMID: 24924355     DOI: 10.1002/jcb.24871

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  33 in total

1.  Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.

Authors:  Kei Kawaguchi; Kentaro Igarashi; Takashi Murakami; Tasuku Kiyuna; Ming Zhao; Yong Zhang; Scott D Nelson; Tara A Russell; Sarah M Dry; Arun S Singh; Bartosz Chmielowski; Yunfeng Li; Michiaki Unno; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-06-16       Impact factor: 4.534

2.  Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.

Authors:  Shuya Yano; Kiyoto Takehara; Ming Zhao; Yuying Tan; Qinghong Han; Shukuan Li; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

3.  Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Takashi Murakami; Tasuku Kiyuna; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jane Yanagawa; Tara A Russell; Arun S Singh; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-05-11       Impact factor: 4.534

4.  The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago.

Authors:  Takashi Murakami; Tasuku Kiyuna; Kei Kawaguchi; Kentaro Igarashi; Arun S Singh; Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Kentaro Miyake; Scott D Nelson; Sarah M Dry; Yunfeng Li; Jonathan C DeLong; Thinzar M Lwin; Takashi Chishima; Kuniya Tanaka; Michael Bouvet; Itaru Endo; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-03-15       Impact factor: 4.534

5.  Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Authors:  Norihiko Sugisawa; Takashi Higuchi; Qinghong Han; Chihiro Hozumi; Jun Yamamoto; Yoshihiko Tashiro; Hiroto Nishino; Kei Kawaguchi; Michael Bouvet; Takuya Murata; Michiaki Unno; Robert M Hoffman
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

6.  Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.

Authors:  Kazuhide Sato; Hirofumi Hanaoka; Rira Watanabe; Takahito Nakajima; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Cancer Ther       Date:  2014-11-21       Impact factor: 6.261

7.  Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy.

Authors:  Shuya Yano; Yong Zhang; Ming Zhao; Yukihiko Hiroshima; Shinji Miwa; Fuminari Uehara; Hiroyuki Kishimoto; Hiroshi Tazawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.

Authors:  Kentaro Igarashi; Kei Kawaguchi; Tasuku Kiyuna; Kentaro Miyake; Masuyo Miyake; Shukuan Li; Qinghong Han; Yuying Tan; Ming Zhao; Yunfeng Li; Scott D Nelson; Sarah M Dry; Arun S Singh; Irmina A Elliott; Tara A Russell; Mark A Eckardt; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Tsuchiya; Fritz C Eilber; Robert M Hoffman
Journal:  Cell Cycle       Date:  2018-04-10       Impact factor: 4.534

9.  Salmonella typhimurium A1-R Exquisitely Targets and Arrests a Matrix-producing Triple-negative Breast Carcinoma in a PDOX Model.

Authors:  Kazuyuki Hamada; Yusuke Aoki; Jun Yamamoto; Chihiro Hozumi; Ming Zhao; Takuya Murata; Norihiko Sugisawa; Michael Bouvet; Takuya Tsunoda; Robert M Hoffman
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

10.  Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models.

Authors:  Yukihiko Hiroshima; Yong Zhang; Ming Zhao; Nan Zhang; Takashi Murakami; Ali Maawy; Sumiyuki Mii; Fuminari Uehara; Mako Yamamoto; Shinji Miwa; Shuya Yano; Masashi Momiyama; Ryutaro Mori; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.